Sonire has developed Next Gen US-guided HIFU therapy system using technology and know-how generated by Tokyo Women’s Medical University, Tohoku University and Tokyo Medical University for cancer treatment. It is expected to be a new therapeutic modality for intractable cancer like pancreatic cancer.
CarbGeM aims to overcome the problem of antimicrobial resistance through cutting-edge biology and digital technology, cross-industrial and cross-disciplinary collaboration including medicine and engineering, and industry-government-academia collaboration with world leading hospitals and research institutions. Our AI-based product assists physicians and laboratory technicians in estimating the species of bacterial infections and selecting appropriate antimicrobial agents.
iCorNet.Laboratory Co. is an academia driven medical device venture from Nagoya University Japan, developing the cardiac support net for heart failure and Lethal arrhythmia. Our device for HF is Patient-Specific Design and Manufactured by 3D knitting machine individually. It fills the treatment gap between ongoing drug therapy and heart transplantation (HTx), and is an alternative to Ventricular Assist Device (VAD)．Our device for lethal arrhythmia (ICD cardiac net) proves painless defibrillation (<0.7J) in both large animal model and computer simulation. Both devices have possibility to be gamechangers of current treatments.
atDose was founded on September 1, 2017 in Yokohama City, Kanagawa, Japan. We are developing a mobile-type dosing and infusion device that can dispense ultra-small doses at precise target points. The lightweight portable intravenous device can be used to support the treatment of diseases such as brain tumors, retinal disease, and breast cancer. With this device, we aim to create a medication platform that will fundamentally change the conventional treatment of serious diseases. For example, side effects such as stomatitis, hair loss, and nausea with anticancer drugs are one of eternal difficulty of medicine. Our ultra-micro-dosing device enables localized, targeted and continuous dosing. Thus, side effects should be reduced while maintaining the efficacy of the drug. Since an animal study has proved our device efficacy, we can go through clinical trial of any cancer therapy. Furthermore, any drug combination can be freely applied with newly approvable dosing amount, therefore, our device will be a novel drug delivery system as a platform technology. We also aim to improve patients' Quality of Life (QoL) with increasing the option of medication procedure. In addition to the conventional treatment, our platform technology will provide an additional procedure that respects patients' preference of QoL . We strongly believe this will improve present medication.
We have been working to bring unique acoustic inventions to markets for 16 years. Located in Tokyo, Japan. First product was a medical device called "Lung Flute" and it is currently used to find active Tuberculosis cases in developing countries. Now, we have developed and patented a new tire technology to contribute for future mobility society.
Hynts Tech is a university startup established in July 2021. We develop and manufacture tools for introducing substances such as DNA, RNA, proteins, or intracellular organelles into cells, or for extracting intracellular materials, and to process cells using these tools.